A bipartisan congressional report estimates overdose deaths cost the United States $1 trillion yearly; 4 states announce plans to lift their statewide mask mandates for schools; study finds greater risk of pregnancy complications in expectant mothers with moderate COVID-19 symptoms.
A new bipartisan congressional report published today found that drug overdoses, primarily those stemming from synthetic opioids, have cost the United States approximately $1 trillion yearly. ABC News reports that drug overdose deaths have more than doubled in recent years, rising from 44,000 to 2013 to over 100,000 between May 2020 and April 2021. As opioid drugs, particularly fentanyl, continue to drive record overdose deaths, a bipartisan congressional commission advocated for a multipronged strategy and cabinet-level leadership to counter the worsening overdose epidemic.
NPR reports that 4 states, Oregon, New Jersey, Connecticut, and Delaware, have announced plans this week to lift their respective statewide mask mandates for schools. The loosening COVID-19 restrictions are set to take effect in Connecticut on February 28, the earliest of the 4 states, with Oregon and Delaware noted as the latest to set plans for March 31. The mask mandate in New Jersey will lift for both students and employees beginning March 7, with districts allowed to require masking thereafter to control any spikes in infections.
As reported by USA Today, a study funded by the National Institutes of Health highlighted the protective benefits of vaccines for expectant mothers and their babies, in utero and after birth. Including 13,000 expectant mothers in the analysis, of which 2400 were infected, findings indicated that pregnant women with moderate COVID-19 symptoms were at greater risk for pregnancy complications than those not infected or with mild to no symptoms. Complications included higher chances of requiring cesarean section, delivering preterm, and mortality around the time of birth.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More